US digital medical magazine Healthcare Tech Outlook profiling the enhancing effect of Veyonda on radiotherapy seen in pre-clinical trials and in clinical trials with men with prostate cancer.
Video: CEO Dr Greg van Wyk discusses anti-prostate cancer drug Veyonda, its efficacy in prostate cancer treatment, the drug’s upside and the company’s strategy for growth.
Independent news service, Biotech Dispatch interviews Noxopharm Founder and Exec Chairman Dr Graham Kelly on Veyonda's effect on cancer cells and the immune system.
